SUVEN — Suven Life Sciences Income Statement
0.000.00%
- IN₹51.47bn
- IN₹50.87bn
- IN₹66.56m
Annual income statement for Suven Life Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | C2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 135 | 118 | 135 | 117 | 66.6 |
Cost of Revenue | |||||
Gross Profit | 134 | 117 | 132 | 107 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 975 | 1,345 | 1,395 | 1,387 | 1,783 |
Operating Profit | -840 | -1,226 | -1,260 | -1,270 | -1,716 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -775 | -1,220 | -1,183 | -1,061 | -1,607 |
Provision for Income Taxes | |||||
Net Income After Taxes | -722 | -1,220 | -1,183 | -1,051 | -1,607 |
Net Income Before Extraordinary Items | |||||
Net Income | -722 | -1,220 | -1,183 | -1,051 | -1,607 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -722 | -1,220 | -1,183 | -1,051 | -1,607 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.22 | -9.32 | -6.97 | -5.04 | -7.37 |